Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 6/20 | 0.78 |
| ▸ | TLR7 | Q9NYK1 | 12/20 | 0.46 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20760756 | 0.88 | NLRP3 (1.00) | NLRP3TLR7TLR8KCNH2 | |
| SCHEMBL30815813 | 0.88 | NLRP3 (1.00) | NLRP3TLR7TLR8KCNH2 | |
| SCHEMBL20761668 | 0.85 | NLRP3 (0.82) | NLRP3TLR7TLR8KCNH2 | |
| SCHEMBL30842218 | 0.84 | NLRP3 (0.54) | NLRP3TLR7TLR8KCNH2 | |
| SCHEMBL20475982 | 0.84 | NLRP3 (0.54) | NLRP3TLR7TLR8KCNH2 | |
| SCHEMBL20761531 | 0.74 | NLRP3 (0.88) | NLRP3 | |
| SCHEMBL21550197 | 0.73 | NLRP3 (0.73) | NLRP3TLR7TLR8KCNH2 | |
| SCHEMBL20761645 | 0.73 | TLR7 (0.45) | NLRP3TLR7TLR8 | |
| SCHEMBL22814393 | 0.71 | NLRP3 (0.69) | NLRP3TLR7TLR8KCNH2 | |
| SCHEMBL20760567 | 0.70 | NLRP3 (0.69) | NLRP3TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067649-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240067649-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2024-02-29 | — | — | US | disclosed |
| US-11827632-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827632-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2023-11-28 | — | — | US | disclosed |
| EP-3753938-A1 | SUBSTITUTED IMIDAZO-QUINOLINES AS NLRP3 MODULATORS | Innate Tumor Immunity, Inc. (US) | 2020-12-23 | — | — | EP | disclosed |
| US-20200157096-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2020-05-21 | — | — | US | disclosed |
| US-20190055236-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY, INC. | 2019-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827632-B2 | NLRP3 modulators | NLRP3, NLRP1, NOD1 | NLRP3 1/4885TLR7 34/4885TLR8 47/4885 |
| US-20190055236-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, NOD1 | NLRP3 1/4885TLR7 34/4885TLR8 47/4885 |
| US-20200157096-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, NOD1 | NLRP3 1/4885TLR7 34/4885TLR8 47/4885 |
| US-20240067649-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, NOD1 | NLRP3 1/4885TLR7 34/4885TLR8 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.